10/25
12:00 pm
ocup
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
Neutral
Report
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
10/23
02:40 pm
ocup
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $10.00. They now have a "buy" rating on the stock.
10/23
09:05 am
ocup
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
High
Report
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
10/22
04:05 pm
ocup
Ocuphire Pharma Announces Acquisition of Opus Genetics
High
Report
Ocuphire Pharma Announces Acquisition of Opus Genetics
9/30
08:00 am
ocup
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Low
Report
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
9/5
08:52 pm
ocup
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia [Yahoo! Finance]
Medium
Report
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia [Yahoo! Finance]
9/5
08:43 pm
ocup
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Medium
Report
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
9/5
08:00 am
ocup
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Low
Report
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia